Pfizer forecasts lower 2026 profit amid drop in COVID product sales
Pfizer warned that its 2026 profit is expected to fall short of analysts’ estimates due to a sharp decline in COVID-19 product sales and the loss of exclusivity on certain drugs.
The company expects adjusted earnings per share of $2.80–3.00, below the $3.05 analysts’ forecast, and revenue of $59.5–62.5 billion. COVID products and lost exclusivity are each expected to reduce revenue by around $1.5 billion.
Pfizer continues its cost-cutting program, targeting more than $7.7 billion in savings through 2027. R&D expenses for 2026 are projected at $10.5–11.5 billion, reflecting ongoing development from Metsera and 3SBio.
Pfizer shares rose slightly in premarket trading following the release of the forecast.
UCapital Asset Management LLP or group companies may have commercial relationships with the companies mentioned. This content is not financial advice.
Sign up for free to ask the AI about this article.
Growth, inflation and rates across the major economies, with the impact on your business.